Holen Sie sich die Stockscreener-App
113.66
0.98%
1.10
Handel nachbörslich:
113.66
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$112.56
Offen:
$113.28
24-Stunden-Volumen:
106.50K
Relative Volume:
0.91
Marktkapitalisierung:
$2.19B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
45.28
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-1.78%
1M Leistung:
+11.83%
6M Leistung:
+4.83%
1J Leistung:
+34.05%
1-Tages-Spanne:
$111.72
$114.68
1-Wochen-Bereich:
$111.72
$116.61
52-Wochen-Spanne:
$81.74
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
113.66 | 2.19B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Wealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com
Rhumbline Advisers Has $6.04 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals CLO Andrew Reardon sells $57,270 in shares - Investing.com Australia
Ligand Pharmaceuticals CLO Andrew Reardon sells $57,270 in shares By Investing.com - Investing.com South Africa
3 Companies That May Be Trading Below Their Estimated Value - Yahoo Finance
Ligand Announces 2025 Investor Day in New York City | LGND Stock News - GuruFocus
Ligand Pharmaceuticals to Host Investor Day in New York City on December 9, 2025 - Nasdaq
Ligand Announces 2025 Investor Day in New York City - Bluefield Daily Telegraph
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of “Buy” from Brokerages - Defense World
GAMMA Investing LLC Purchases 61,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ligand Pharmaceuticals Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017LGND - ACCESS Newswire
BNP Paribas Financial Markets Cuts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Lazard Asset Management LLC Sells 1,507 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Bank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Executives At Ligand Pharmaceuticals Show Confidence With Major Stock Buys - Finimize
Jane Street Group LLC Sells 1,083 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ameriprise Financial Inc. Raises Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 - TradingView
The Manufacturers Life Insurance Company Buys 779 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Executives Increase Holdings - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.com - Defense World
LGND: 1Q:25 Results - MSN
Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Oppenheimer Maintains Rating and Raises Price Target for LGND | - GuruFocus
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2025 Earnings Call Transcript - Insider Monkey
Oppenheimer Maintains Rating and Raises Price Target for LGND | LGND Stock News - GuruFocus
Oppenheimer Raises Price Target for Ligand (LGND) to $145 | LGND Stock News - GuruFocus
Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating - marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ligand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highligh - GuruFocus
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations - Investing.com
Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth - TipRanks
Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Ligand: Q1 Earnings Snapshot - Huron Daily Tribune
Earnings call transcript: Ligand Pharmaceuticals beats Q1 2025 expectations By Investing.com - Investing.com UK
Ligand Pharmaceuticals Q1 Core Adjusted Earnings, Revenue Increase; Shares Up Pre-Bell - marketscreener.com
Ligand (LGND) Upholds 2025 Financial Guidance | LGND Stock News - GuruFocus
Ligand Pharmaceuticals Reports Q1 Revenue of $45.3M, Beating Estimates; EPS Falls Short with $2.21 Loss - GuruFocus
Ligand (LGND) Exceeds Revenue Expectations with Strategic Moves - GuruFocus
Ligand (LGND) Exceeds Revenue Expectations with Strategic Moves | LGND Stock News - GuruFocus
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):